State of Alaska Department of Revenue Has $791,000 Stock Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

State of Alaska Department of Revenue lessened its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.6% in the fourth quarter, HoldingsChannel reports. The fund owned 21,325 shares of the company’s stock after selling 342 shares during the period. State of Alaska Department of Revenue’s holdings in Amphastar Pharmaceuticals were worth $791,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacer Advisors Inc. boosted its holdings in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company’s stock valued at $50,139,000 after purchasing an additional 1,347,775 shares during the period. Boston Trust Walden Corp raised its position in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company’s stock valued at $36,347,000 after buying an additional 439,281 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amphastar Pharmaceuticals by 1.5% in the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company’s stock valued at $44,674,000 after buying an additional 14,015 shares during the period. Portolan Capital Management LLC grew its position in Amphastar Pharmaceuticals by 201.1% during the third quarter. Portolan Capital Management LLC now owns 327,764 shares of the company’s stock worth $15,906,000 after buying an additional 218,901 shares in the last quarter. Finally, Nordea Investment Management AB increased its stake in Amphastar Pharmaceuticals by 4.8% during the 4th quarter. Nordea Investment Management AB now owns 279,714 shares of the company’s stock worth $10,386,000 after acquiring an additional 12,851 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $31.02 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.49 billion, a PE ratio of 10.34, a price-to-earnings-growth ratio of 2.07 and a beta of 0.81. Amphastar Pharmaceuticals, Inc. has a twelve month low of $30.95 and a twelve month high of $56.38. The stock’s 50-day simple moving average is $36.87 and its 200 day simple moving average is $43.33.

Insider Activity

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the transaction, the director now directly owns 30,471 shares in the company, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Rong Zhou sold 7,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now owns 118,469 shares in the company, valued at approximately $5,262,392.98. This trade represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on AMPH. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. Piper Sandler downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $66.00 to $36.00 in a research note on Tuesday, February 4th. Finally, StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus price target of $50.33.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.